## Senator Wiklund from the Committee on Health and Human Services, to which was referred

S.F. No. 328: A bill for an act relating to health; requiring manufacturers to report and maintain prescription drug prices; requiring the filing of health plan prescription drug formularies; health care coverage; establishing requirements for a prescription benefit tool; requiring prescription drug benefit transparency and disclosure; amending Minnesota Statutes 2022, sections 62A.02, subdivision 1; 62J.497, subdivisions 1, 3; 62J.84, subdivisions 2, $6,7,8,9 ; 151.071$, subdivision 2 ; proposing coding for new law in Minnesota Statutes, chapters $62 \mathrm{~J} ; 62 \mathrm{Q}$.

Reports the same back with the recommendation that the bill be amended as follows:

Page 1, line 19, after the period, insert "Proposed revisions to the health plan's prescription drug formulary must be filed with the commissioner no later than August 1 of the application year."

Page 6, line 4, delete "March" and insert "志y" and delete "March" and insert "July"

Page 6, lines 27 and 28, delete "May" and insert "October"
Page 7, line 2, delete everything before the period and insert "may increase the wholesale acquisition cost of the drug for the next calendar year only after providing the commissioner with at least 90 days' written notice"

Page 14 , line 13 , delete "year" and insert "quarter"
Page 15 , line 12 , after the comma, insert "or a biosimilar as defined by United States Code, title 42, section 262(i)(2),"

And when so amended the bill do pass and be re-referred to the Committee on Commerce and Consumer Protection. Amendments adopted. Report adopted.

(Committee Chair)

March 1, 2023
(Date of Committee recommendation)

